Segment Information and Concentration of Business Risk (Tables)

12 Months Ended

Dec. 31, 2016

Segment Information and Concentration of Business Risk [Abstract]

Segment Information

The following is our segment information for 2016, 2015 and 2014 (in thousands).

2016	Ionis Core		Akcea Therapeutics			Elimination of Intercompany Activity			Total
Revenue:
Research and development	$	338,546	$	—		$	(12,648	)	$	325,898
Licensing and royalty		20,722		—			—			20,722
Total segment revenue	$	359,268	$	—		$	(12,648	)	$	346,620
Income (loss) from operations	$	37,196	$	(83,512	)	$	—		$	(46,316	)

2015	Ionis Core			Akcea Therapeutics			Elimination of Intercompany Activity			Total
Revenue:
Research and development	$	284,135		$	—		$	(2,775	)	$	281,360
Licensing and royalty		2,343			—			—			2,343
Total segment revenue	$	286,478		$	—		$	(2,775	)	$	283,703
Loss from operations	$	(23,014	)	$	(52,748	)	$	—		$	(75,762	)

2014	Ionis Core			Akcea Therapeutics			Total
Revenue:
Research and development	$	202,514		$	—		$	202,514
Licensing and royalty		11,647			—			11,647
Total segment revenue	$	214,161		$	—		$	214,161
Loss from operations	$	(26,033	)	$	(21,697	)	$	(47,730	)

The following table shows our total assets by segment at December 31, 2016 and 2015 (in thousands), respectively.

Total Assets	Ionis Core		Akcea Therapeutics		Elimination of Intercompany Activity			Total
December 31, 2016	$	1,067,770	$	10,684	$	(165,987	)	$	912,467
December 31, 2015	$	994,191	$	66,068	$	(112,359	)	$	947,900

Revenue from Significant Partners

We have historically funded our operations from collaborations with corporate partners and a relatively small number of partners have accounted for a significant percentage of our revenue. Revenue from significant partners, which is defined as 10 percent or more of our total revenue, was as follows:

	2016		2015		2014
Partner A		60 %		37 %		58 %
Partner B		19 %		2 %		13 %
Partner C		4 %		12 %		17 %
Partner D		2 %		33 %		0 %
Partner E		2 %		11 %		4 %